Generation of CEA-specific T-cell response in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients following vaccination with dendritic cells loaded with CEA peptides.

CMUR > College of Pharmacy > School of Pharmacy/Master Degree Program, Ph. D program > Journal articles > Item 310903500/7701

Please use this identifier to cite or link to this item: http://ir.cmu.edu.tw/ir/handle/310903500/7701

Title:	Generation of CEA-specific T-cell response in HLA-A0201 and HLA-A2402 late-stage colorectal cancer patients following vaccination with dendritic cells loaded with CEA peptides.
Authors:	(Liu, K.-J.*);(Wang, C.-C.);(Chen, L.-T.);(Cheng, A.-L.);(Lin, D.-T.);(Wu, Y.-C.);(Yu, W.-L);(Hung, Y.-M.);莊聲宏(Shin-Hun Juang);(Whang-Peng, J)
Contributors:	藥學院藥學系;中國附醫醫學研究部細胞及基因治療研究室
Date:	2004-04
Issue Date:	2009-08-26 16:34:22 (UTC+8)
Abstract:	Purpose: We intranodally immunized metastatic colorectal carcinoma patients, who had failed standard chemotherapy, with dendritic cells (DCs) pulsed with HLA-A0201- or HLA-A2402-restricted carcinoembryonic antigen (CEA) peptides to evaluate the safety of this treatment and the immune response against CEA peptides before and after the treatment. Experimental Design: Six patients with the HLA-A2402 genotype and 4 patients with the HLA-A0201 genotype were enrolled. A single CEA peptide (YLSGANLNL) or two CEA peptides (QYSWFVNGTF and TYACFVSNL) were used for patients with the HLA-A0201 or HLA-A2402 genotype, respectively. Autologous DCs were generated by culturing adherent mononuclear cells with interleukin 4 and granulocyte macrophage colony-stimulating factor for 6 days. Maturation of DCs was then induced with tumor necrosis factor α for 40 h. Mature DCs were pulsed with appropriate CEA peptides for 2 h. After washing, 1 million peptide-pulsed DCs were injected into one inguinal lymph node under sonographic guidance. Each patient received four injections. Results: No grade II/III toxicity or autoimmunity was observed. An increase in the number of CEA-specific T cells after DC vaccination could be detected in 7 of 10 (70%) patients. Two (20%) patients had stable disease for at least 12 weeks. One of these 2 patients experienced a transient decrease in CEA levels during the treatment period and also had the most significant T-cell response against the immunizing CEA peptides. Conclusions: These results suggest that our vaccination procedure can generate or boost specific T-cell responses and may provide clinical benefit in certain cancer patients.
Relation:	CLINICAL CANCER RESEARCH 10(8 )2645 ~2651
Appears in Collections:	[School of Pharmacy/Master Degree Program, Ph. D program] Journal articles

Files in This Item:

File	Size	Format
	58Kb	Unknown	224	View/Open

Loading...